We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BriaCell Therapeutics Corporation | NASDAQ:BCTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0496 | -5.91% | 0.79 | 0.7801 | 0.79 | 0.85 | 0.7601 | 0.82 | 672,688 | 19:13:55 |
“Excitement is taking root within BriaCell as we progress towards our upcoming Bria-OTS™ clinical trial, where we will be matching our immunotherapy to each patient's HLA type with the goal of increasing the likelihood of clinical benefit,” remarked Dr. Miguel A. Lopez-Lago, Senior Director, R&D. “We intend to treat each patient with a personalized formulation, based on a simple saliva test that determines each patient's HLA types.”
Poster presentation details are summarized below:
Poster Title: Toward a Personalized Off-the-Shelf Cellular Immunotherapy for Cancer
Summary:
Bria-OTS™ immunotherapy design
Patients that match Bria-IMT™ cell line at least at 1 HLA allele are more likely to derive clinical benefit. Therefore, BriaCell has genetically modified the Bria-IMT™ cell line to match more patients. Based on population analysis, BriaCell has genetically engineered the Bria-IMT™ parent cell line to express 8 Class I and 7 Class II HLA types. The Class I and Class II regions refer to the genes coding for molecules HLA-A, -B, -C, and HLA-DR, -DQ, –DP, respectively. Four cell lines have been developed, each engineered to express four HLA alleles: two HLA-A alleles and two HLA-DRB alleles. The new cell therapy would be able to match >99% of the population at least at one HLA type.
Manufacturing of Bria-OTS™ immunotherapies for upcoming clinical trial
A copy of the poster has been posted at the following: https://briacell.com/scientific-publications/.
Personalized breast cancer treatment using Bria-OTS™
To increase the likelihood of therapeutic response, BriaCell will treat each patient with the optimized premanufactured Bria-OTS™ formulation, based on individual specific HLA type. A simple saliva test that determines HLA types will be used to categorize patients. In BriaCell’s current and active Bria-IMT™ Phase I/IIa clinical trial, BriaCell had previously reported average overall survival benefit of 13.4 months in patients with 2+ HLA matches (average of 5 prior regimens)1 versus 7.2-9.8 months in historical comparison treatment trials (2 prior regimens)2.
(1) | BriaCell treats severely sick patients, as indicated by the “prior regimens” figures, indicating the number of therapies these patients had failed prior to treatment with Bria-IMT™. |
(2) | Overall survival of 7.2-9.8 months was reported in similar patients with metastatic breast cancer who have failed 2 prior therapy attempts (third line setting); Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17. To more accurately present survival data, BriaCell has included only those women able to mount an immune response. |
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include, among others, statements the Company makes regarding: (i) the outcome of the testing and clinical production of the Bria-OTS™ cell lines, (ii) the safety and efficacy of any potential treatment regime with Bria-OTS™, and (iii) when and whether Bria-OTS™ will enter an open-label Phase I/IIa clinical trial. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE IRinvestors@briacell.com
1 Year BriaCell Therapeutics Chart |
1 Month BriaCell Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions